Tilray TLRY Stock CRASH? Q1 2027 Earnings Preview + DEA Rescheduling UPDATE | Buy or Sell Now?

AI-generated source summary

The video presents a fundamental analysis of Tilray Brands (TLRY), highlighting its significant stock price decline over the past five years (-96%) and its recent 52-week low of $3.54. Despite a projected revenue growth of 27.5% for Q1 2027, the company is expected to report a net loss of $19.5 million, with a market capitalization below $600 million. A key concern is the divergence between revenue growth and profitability, as adjusted EBITDA growth significantly outpaces revenue growth, indicating margin expansion challenges. Cannabis and beverage margins have been compressed over the last year. Regulatory overhang, particularly concerning the DEA's stance on cannabis rescheduling and the potential delay of decisions past midterm elections, poses a risk. The company's diversification strategy into beverages and wellness is noted, with expectations of $200 million in annual revenue and $6-8 million in adjusted EBITDA from its brewing and beverage operations. However, concerns remain about acquisitions masking organic weaknesses, with core cannabis business growing only 5%. The analysis points out that a price-to-sales ratio is less meaningful for companies without earnings, and investors should focus on metrics like adjusted EBITDA margin, international cannabis revenue, free cash flow, and the contribution from its brewing segment. The final verdict suggests TLRY is a highly speculative bet on regulatory changes, with a projected upside to $7.00 if regulatory hurdles are cleared, but a downside risk to $2.82 if current trends persist.

AI-generated summary based on the source content.